Compare NBTX & BTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | BTZ |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | N/A |
| Metric | NBTX | BTZ |
|---|---|---|
| Price | $22.35 | $10.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 46.3K | ★ 279.4K |
| Earning Date | 09-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.41 |
| Revenue | ★ $11,930,711.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $136.64 | N/A |
| P/E Ratio | ★ N/A | $7.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.82 | $9.10 |
| 52 Week High | $30.35 | $11.13 |
| Indicator | NBTX | BTZ |
|---|---|---|
| Relative Strength Index (RSI) | 57.88 | 42.24 |
| Support Level | $20.83 | $10.75 |
| Resistance Level | $22.05 | $10.87 |
| Average True Range (ATR) | 0.89 | 0.09 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 88.34 | 32.35 |
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.